NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) today announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral ...

September 18, 2013: Strides Arcolab Limited (BSE: 532531, NSE: STAR) today announced that it has received US FDA approval for Beltapharm's facility at Milan, Italy. This state-of-the-art, EU and TGA ...

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that ...

Bangalore-based Strides Arcolab Ltd has sold its entire 94 per cent holding in Ascent Pharma Health Ltd, its subsidiary operating in Australia and South-east Asia, to NYSE-listed Watson ...

The funds will be raised by way of issue of GDRs/ADRs /FCCBs/QIP or such other equity linked instruments Strides Arcolab plans to raise Rs 1500 crore through various market instruments “The Board of ...

Banking, financial, auto, pharma, liquor and paints sectors will be getting astrological support says Satish Gupta of Astrostocktips. Firstcall Research is bullish on Stride Arcolab and has ...

Drugmaker Strides Shasun Ltd said on Friday it will buy Sweden-based Moberg Pharma's paediatric brand – PediaCare – for $5 ..... Drugmaker Strides Shasun Ltd said on Wednesday it has received board ...

{mosimage}Indian pharma major Strides Arcolab returns to Australia after three years. It announced today that it is to acquire a generic pharmaceutical business and related assets from Aspen for ...

Mumbai: Maker and exporter of finished pharma dosage forms, Strides Arcolab will raise up to $100 million (over ₹ 400 crore) through an FCCB issue to part-finance potential overseas acquisition plans.

BANGALORE, Indiaand CRANBURY, N.J., July 16, 2014 /PRNewswire/ -- Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc ...

The agreement involves transfer of Ranbaxy’s Solus and Solus Care divisions, along with employees to Strides for a consideration of Rs 1,650 million Sun Pharmaceutical Industries and Strides Arcolab ...